Platelet function after single [153Sm]EDTMP therapy in prostate cancer.
OBJECTIVE
Aim of the study was to assess whether [153Sm] EDTMP therapy at a low-dose is associated with platelet activation.


METHODS
In 29 patients suffering from metastatic prostate cancer platelet count and various platelet function parameters have been monitored for 2 months after a single (the first) application of 1.1 GBq mCi [153Sm]EDTMP.


RESULTS
After 3 days insignificant signs of platelet activation (increase in malondialdehyde, adenosine diphosphate-induced platelet aggregation, decreased platelet sensitivity) occur, normalizing rapidly. At the nadir of platelet count (3-4 weeks) platelet aggregation response in non-count adjusted samples is somewhat lower, while activity per cell (count adjusted samples) is unchanged. Platelet proteins do not change at all. Insignificant activation of platelet function at day 3 is interpreted as an indicator of mild oxidation injury, late aggregation response changes in non-adjusted samples seem only to reflect temporarily decreased number of circulating platelets. Samarium-153-EDTMP therapy at doses (1.1 GBq) used in the Vienna-protocol is not associated with a significantly altered functional behavior of platelets.


CONCLUSIONS
We conclude that a single dose of 1.1 GBq 153Sm-EDTMP does not significantly affect in vivo and ex vivo platelet function.
Weiss
K
K
Department of Nuclear Medicine, Hospital Wr. Neustadt, Austria.
Palumbo
B
B
Palumbo
I
I
Palumbo
R
R
Granegger
S
S
Hiltunen
J
J
Sinzinger
H
H
D000368:Aged; D001792:Blood Platelets / Q000528:radiation effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D015539:Platelet Activation / Q000528:radiation effects*; D010976:Platelet Count; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000097:blood / Q000209:etiology; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals; C061972:samarium Sm-153 lexidronam